Ken Griffin Immatics N.V. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$10.93 - $12.92 $260,134 - $307,496	-23,800 Reduced 27.9%	61,500 $701,000
Q2 2024 Aug 14, 2024	SELL	$9.78 - $13.49 $45,966 - $63,403	-4,700 Reduced 5.22%	85,300 $991,000
Q1 2024 May 15, 2024	BUY	$10.23 - $12.94 $570,834 - $722,052	55,800 Added 163.16%	90,000 $945,000
Q4 2023 Feb 14, 2024	SELL	$7.36 - $10.89 $39,744 - $58,806	-5,400 Reduced 13.64%	34,200 $360,000
Q3 2023 Nov 14, 2023	SELL	$11.01 - $12.62 $44,040 - $50,480	-4,000 Reduced 9.17%	39,600 $458,000
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $147,408 - $316,728	24,900 Added 133.16%	43,600 $503,000
Q1 2023 May 15, 2023	SELL	$6.74 - $9.44 $51,898 - $72,688	-7,700 Reduced 29.17%	18,700 $129,000
Q4 2022 Feb 14, 2023	SELL	$8.05 - $11.58 $42,665 - $61,374	-5,300 Reduced 16.72%	26,400 $229,000
Q3 2022 Nov 14, 2022	BUY	$3.31 - $13.06 $104,927 - $414,002	31,700 New	31,700 $317,000

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $522M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.